From our September 2020 Newsletter

CHMP Grants Positive Opinion for Expanded Use of Otsuka’s Deltyba® (delamanid) in Children and Adolescents Weighing at Least 30kg Treated for Pulmonary Multi-drug Resistant Tuberculosis

The European Medicines Agency has updated its stance on Deltyba—with implications for children with DR-TB.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

The driving contributor to safer, all-oral TB regimens may not be who you think, with more credit due to the government than private enterprises.

From our August 2020 Newsletter

Union welcomes EC authorization of TB Alliance’s BPaL treatment for drug-resistant TB
On August 3rd, a new treatment developed by the TB Alliance has been approved by the European Commission for some of the most drug-resistant forms of TB. Learn more about the new Pretomanid drug here.

From our July 2020 Newsletter

COVID-19 Disruptions May Raise Cancer, HIV, TB Cases, Deaths Globally
Mounting evidence suggests the ongoing pandemic will have significant implications for the treatment and pathology of other burdensome diseases—tuberculosis included.

Rapid Drug-Resistant Tuberculosis Diagnostics Test is Launched
The new Xpert MTB/XDR from Cepheid offers huge advancements in the profiling of MDR and XDR-TB—minimizing turnaround time and complexity while increasing accessibility.


From our June 2020 Newsletter

FDA Approves Pediatric Formulation of Bedaquiline for Multidrug-Resistant TB
Bedaquiline first received approval from the FDA in 2012 for use in adult patients. Now, the FDA has given Johnson & Johnson accelerated approval to use the drug on pediatric patients five years and older. You can access the FDA’s updated label for the drug here.

Tuberculosis in Children: Underdiagnosed and Undertreated
A deeper dive into comprehensive, up-to-date information on treating tuberculosis in children.

TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen
Mylan’s new Named Patient Access Program has been designed to make pretomanid accessible in countries previously lacking access to the drug.

From our May 2020 Newsletter

EMA panel backs pretomanid for drug-resistant TB (Also from our April 2020 Newsletter)

Posted on 23 Apr 2020

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).

Webinar: Hear the latest about the NiX-TB regimen for XDR-TB; Slides and Recording here!

Posted on 30 Mar 2020

On March 26, 2020, RESIST-TB hosted a webinar featuring Dr. Dan Everitt to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant tuberculosis (XDR-TB). To read the publication, the article can be found below (publication #2). The presentation slides can be found below, and the recording can be found here.

WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance


Posted on 16 Jan 2020
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO).

Webinar: Advocacy for access to DR-TB treatment - webinar materials now available online


Posted on 16 Jan 2020
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment.



© 2023 by Last Chance. Proudly created with